Temperature-sensitive recombinant collagen sterile mask and method for preparing the same

Abstract

The application discloses a kind of temperature-sensitive recombinant collagen sterile mask and preparation method thereof.The mask is by hydroxypropyl chitin 1wt%-3.5wt%, recombinant III type humanized collagen 0.01wt%-0.5wt%, recombinant I type humanized collagen 0.01wt%-0.5wt%, glycerol 0.1wt%-10wt%, eriodictyol 0.001wt%-0.015wt%, asiaticoside 0.1wt%-2wt% and water according to mass percentage.The sterile mask of the application is in the form of viscous liquid below 25 DEG C, each efficacy component can be uniformly distributed in system, when coating to face, temperature increases to body temperature, solution phase transition occurs, quickly converts into weak gel, can realize the rapid penetration and sustained release efficacy component to skin to skin, reach deep instant relief and skin repair effect.

Description

Technical Field

[0001] This invention belongs to the field of skin care products and relates to a thermosensitive recombinant collagen sterile facial mask and its preparation method. Background Technology

[0002] As a skin care product, facial masks have the effect of quickly moisturizing and skin care, and have gradually become an indispensable part of people's lives. At present, the high-end facial mask market has the following three problems: (1) In order to ensure the shelf life of the facial mask and inhibit the growth of microorganisms, preservatives and other potentially allergenic chemical ingredients are usually added to the commercially available facial mask liquid, which restricts the use of some people with allergies and consumers after medical beauty surgery such as photon; (2) Non-woven fabrics are used as the base material of the facial mask, which are easy to deform during use, have poor adhesion, and the fixed size of the mask cannot be adapted to the curvature of the consumer's face, resulting in a poor user experience. At the same time, discarding the mask after use will have an adverse impact on the environment; (3) During normal use, the water in the essence evaporates quickly, and the water retention rate is low, resulting in low water retention and a large amount of waste of essence.

[0003] In recent years, an increasing number of people have been troubled by sensitive skin. Sensitive skin is a neurogenic inflammation mediated by transient receptor potentials, manifesting as symptoms such as vasodilation, localized edema, itching, and pain. Studies have shown that heat, photoaging, and natural aging can increase the expression of transient receptor potential vanillic acid channel 1 (TRPV1) in human epidermal keratinocytes. Activated TRPV1 can promote the release of substance P (SP) and calcitonin gene-related peptide (CGRP), thereby causing dysfunction of the skin's sensory nerves, increased vascular reactivity, and immune and inflammatory responses. Therefore, designing and adding TRPV1-specific antagonists to skincare products is an effective strategy for improving sensitive skin.

[0004] Patent CN 110960467 A discloses a sterile facial mask and its preparation method. This sterile mask includes a mask substrate and a nutrient solution, and does not contain preservatives. However, it does not solve the problems of incomplete compatibility of the mask substrate due to individual differences and waste of essence. Patent CN 115737460A discloses a natural moisturizing and antioxidant cream mask and its preparation method. This cream mask solves the problem caused by the mask substrate, but still adds preservatives and other potentially sensitizing chemical ingredients. Summary of the Invention

[0005] The purpose of this invention is to provide a thermosensitive recombinant collagen sterile facial mask and its preparation method. This mask is free of preservatives and non-woven fabrics or other mask substrates, making it suitable for people with sensitive skin.

[0006] The technical solution for achieving the objective of this invention is as follows:

[0007] Thermosensitive recombinant collagen sterile facial mask, by weight percentage, consists of the following ingredients:

[0008] Hydroxypropyl chitosan 1wt%-3.5wt%, recombinant type III humanized collagen 0.01wt%-0.5wt%, recombinant type I humanized collagen 0.01wt%-0.5wt%, glycerol 0.1wt%-10wt%, sennaol 0.001wt%-0.015wt%, asiaticoside 0.1wt%-2wt%, water balance, wherein the mass ratio of asiaticoside to sennaol is 62.5:1-166.7:1. The recombinant type III humanized collagen is produced by fermentation of Pichia pastoris with accession number CGMCC No. 5021, and the recombinant type I humanized collagen is produced by fermentation of Pichia pastoris with accession number CGMCC No. 16461.

[0009] Preferably, the temperature-sensitive recombinant collagen sterile facial mask is composed of the following components by weight percentage:

[0010] Hydroxypropyl chitosan 1.5wt%, recombinant type III humanized collagen 0.1wt%, recombinant type I humanized collagen 0.1wt%, glycerol 5wt%, sennaol 0.003wt%, asiaticoside 0.5wt%, water balance.

[0011] The specific steps for preparing the above-mentioned thermosensitive recombinant collagen sterile facial mask are as follows:

[0012] According to the formula, under stirring conditions at 2-10℃, hydroxypropyl chitin is dissolved in water, and recombinant type III humanized collagen, recombinant type I humanized collagen, glycerin, senna phenol and asiaticoside are added in sequence. After stirring until the mixture is uniform, it is allowed to stand to obtain a semi-transparent solution. The semi-transparent solution is then packaged and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile mask.

[0013] Preferably, in step (1), the water is deionized water, distilled water, water for injection, or physiological saline.

[0014] Preferably, in step (1), the stirring temperature is 4-8℃.

[0015] Preferably, the packaging is a retort pouch, glass bottle, or other packaging that is resistant to moist heat sterilization.

[0016] Compared with the prior art, the present invention has the following advantages:

[0017] (1) The mask formula of the present invention contains only the necessary functional ingredients. Recombinant type III humanized collagen and recombinant type I humanized collagen are human-designed protein materials with good compatibility and do not cause human irritation. Glycerin is a conventional moisturizer. Senna phenol and asiaticoside are plant-extracted active ingredients. They do not contain any preservatives, flavoring agents or other irritating ingredients and have better compatibility.

[0018] (2) By utilizing the synergistic effect of asiaticoside and sennaol, the mask possesses superior antioxidant properties, protecting the skin's capillary microenvironment and effectively improving skin redness. In addition, sennaol can effectively inhibit the overexpression of TRPV1 and effectively soothe the skin; recombinant type I collagen and recombinant type III collagen can promote the production of skin collagen and repair the skin; hydroxypropyl chitosan has a certain degree of deacetylation, and the amino groups on its side chain endow it with a certain degree of antibacterial activity.

[0019] (3) The present invention uses heat-resistant packaging such as retort pouches, and achieves aseptic delivery after moist heat sterilization. This avoids the addition of preservatives and ensures the shelf life of the product. Aseptic delivery is more suitable for use after some medical aesthetic facial minimally invasive injections.

[0020] (4) The mask of the present invention is thermosensitive. At low temperature (less than 25°C), it is liquid and can flow freely. Each component can be evenly distributed inside the product. When used, it gels after being applied to the face (greater than 35°C), which can achieve rapid penetration into the skin and continuous release of effective ingredients to the skin, so as to achieve deep and immediate soothing and skin repair.

[0021] (5) The mask of the present invention does not require a mask sheet and can be directly applied to the area of ​​the face where it is to be used, thus avoiding waste and poor effect caused by the incompatibility between the mask sheet and the face. At the same time, no waste mask sheet is generated after use, which is environmentally friendly. Attached Figure Description

[0022] Figure 1 The phase transition diagram of the sample in Example 5 under cyclic heating and cooling at 8-37°C is shown.

[0023] Figure 2 The bar chart shows the expression levels of TNF-α and IL-6 in HaCaT cells after sample treatment in Examples 5, 6, 7, 8, and 9. Detailed Implementation

[0024] The present invention will now be described in further detail with reference to specific embodiments and accompanying drawings.

[0025] In this invention, the recombinant type III humanized collagen is produced by fermentation of Pichia pastoris with accession number CGMCC No. 5021, which has been fully disclosed in Chinese patent ZL 201110327865.5; the recombinant type I humanized collagen is produced by fermentation of Pichia pastoris with accession number CGMCC No. 16461, which has been fully disclosed in Chinese patent ZL201811589560.X.

[0026] Example 1

[0027] Thermosensitive recombinant collagen sterile facial mask, by weight percentage, consists of the following ingredients:

[0028] Hydroxypropyl chitosan 1 wt%, recombinant type III humanized collagen 0.01 wt%, recombinant type I humanized collagen 0.01 wt%, glycerol 0.1 wt%, sennaol 0.001 wt%, asiaticoside 0.1 wt%, water balance, asiaticoside:sennaol = 100:1. Prepared by the following steps:

[0029] 1g of hydroxypropyl chitin was dissolved in 98.779g of deionized water. After complete dissolution by stirring at 4℃, 0.01g of recombinant type III humanized collagen, 0.01g of recombinant type I humanized collagen, 0.1g of glycerin, 0.001g of senna extract, and 0.1g of asiaticoside were added sequentially. After stirring evenly, the mixture was allowed to stand to obtain a semi-transparent solution. The resulting semi-transparent solution was quantitatively bottled and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile facial mask.

[0030] Example 2

[0031] Thermosensitive recombinant collagen sterile facial mask, by weight percentage, consists of the following ingredients:

[0032] Hydroxypropyl chitosan 1 wt%, recombinant type III humanized collagen 0.5 wt%, recombinant type I humanized collagen 0.01 wt%, glycerol 6 wt%, sennaol 0.005 wt%, asiaticoside 0.5 wt%, water balance, asiaticoside:sennaol = 100:1. Prepared by the following steps:

[0033] 1g of hydroxypropyl chitin was dissolved in 91.985g of deionized water and stirred at 2°C until completely dissolved. Then, 0.5g of recombinant type III humanized collagen, 0.01g of recombinant type I humanized collagen, 6g of glycerin, 0.005g of senna extract, and 0.5g of asiaticoside were added sequentially. After stirring evenly, the mixture was allowed to stand to obtain a semi-transparent solution. The resulting semi-transparent solution was quantitatively bottled and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile facial mask.

[0034] Example 3

[0035] Thermosensitive recombinant collagen sterile facial mask, by weight percentage, consists of the following ingredients:

[0036] Hydroxypropyl chitosan 1.5 wt%, recombinant type III humanized collagen 0.01 wt%, recombinant type I humanized collagen 0.5 wt%, glycerol 2 wt%, sennaol 0.01 wt%, asiaticoside 1 wt%, water balance, asiaticoside:sennaol = 100:1. Prepared by the following steps:

[0037] 1.5g of hydroxypropyl chitin was dissolved in 94.98g of deionized water and stirred at 8°C until completely dissolved. Then, 0.01g of recombinant type III humanized collagen, 0.5g of recombinant type I humanized collagen, 2g of glycerin, 0.01g of sennaol, and 1.0g of asiaticoside were added sequentially. After stirring evenly, the mixture was allowed to stand to obtain a semi-transparent solution. The resulting semi-transparent solution was quantitatively bottled and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile facial mask.

[0038] Example 4

[0039] Thermosensitive recombinant collagen sterile facial mask, by weight percentage, consists of the following ingredients:

[0040] Hydroxypropyl chitosan 3.5 wt%, recombinant type III humanized collagen 0.1 wt%, recombinant type I humanized collagen 0.1 wt%, glycerol 0.1 wt%, sennaol 0.008 wt%, asiaticoside 0.5 wt%, water balance, asiaticoside:sennaol = 62.5:1. Prepared by the following steps:

[0041] 3.5g of hydroxypropyl chitin was dissolved in 95.692g of deionized water and stirred at 10℃ until completely dissolved. Then, 0.1g of recombinant type III humanized collagen, 0.1g of recombinant type I humanized collagen, 0.1g of glycerin, 0.008g of senna extract, and 0.5g of asiaticoside were added sequentially. After stirring evenly, the mixture was allowed to stand to obtain a semi-transparent solution. The resulting semi-transparent solution was quantitatively bottled and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile facial mask.

[0042] Example 5

[0043] Thermosensitive recombinant collagen sterile facial mask, by weight percentage, consists of the following ingredients:

[0044] Hydroxypropyl chitosan 1.5 wt%, recombinant type III humanized collagen 0.1 wt%, recombinant type I humanized collagen 0.1 wt%, glycerol 5 wt%, sennaol 0.003 wt%, asiaticoside 0.5 wt%, water balance; asiaticoside:sennaol = 166.7:1. Prepared by the following steps:

[0045] 1.5g of hydroxypropyl chitin was dissolved in 92.797g of deionized water and stirred at 4℃ until completely dissolved. Then, 0.1g of recombinant type III humanized collagen, 0.1g of recombinant type I humanized collagen, 5g of glycerin, 0.003g of senna extract, and 0.5g of asiaticoside were added sequentially. After stirring evenly, the mixture was allowed to stand to obtain a semi-transparent solution. The resulting semi-transparent solution was quantitatively bottled and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile facial mask.

[0046] Example 6

[0047] Thermosensitive recombinant collagen sterile facial mask, by weight percentage, consists of the following ingredients:

[0048] Hydroxypropyl chitosan 2 wt%, recombinant type III humanized collagen 0.2 wt%, recombinant type I humanized collagen 0.1 wt%, glycerol 10 wt%, sennaol 0.015 wt%, asiaticoside 2 wt%, water balance, asiaticoside:sennaol = 133.3:1. Prepared by the following steps:

[0049] 2g of hydroxypropyl chitin was dissolved in 85.685g of deionized water and stirred at 4℃ until completely dissolved. Then, 0.2g of recombinant type III humanized collagen, 0.1g of recombinant type I humanized collagen, 10g of glycerin, 0.015g of senna extract, and 2.0g of asiaticoside were added sequentially. After stirring evenly, the mixture was allowed to stand to obtain a semi-transparent solution. The resulting semi-transparent solution was quantitatively bottled and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile facial mask.

[0050] Comparative Example 1

[0051] This comparative example is largely the same as Example 5, except that the amount of hydroxypropyl chitosan added is 0.5g, that is, the content of hydroxypropyl chitosan is 0.5wt%.

[0052] Comparative Example 2

[0053] This comparative example is largely the same as Example 5, except that the stirring and dissolving temperature is 25°C.

[0054] Comparative Example 3

[0055] This comparative example is largely the same as Example 5, except that the amount of recombinant type III humanized collagen added is 0.005g, that is, the content of recombinant type III humanized collagen is 0.005wt%.

[0056] Comparative Example 4

[0057] This comparative example is largely the same as Example 5, except that the amount of recombinant type I humanized collagen added is 0.005g, that is, the content of recombinant type I humanized collagen is 0.005wt%.

[0058] Comparative Example 5

[0059] This comparative example is largely the same as Example 5, except that the amount of glycerol added is 0.05g, that is, the content of glycerol is 0.05wt%.

[0060] Comparative Example 6

[0061] This comparative example is largely the same as Example 5, except that no sennaol was added.

[0062] Comparative Example 7

[0063] This comparative example is largely the same as Example 5, except that asiaticoside was not added.

[0064] Comparative Example 8

[0065] This comparative example is largely the same as Example 5, except that the amount of asiaticoside added is 0.15g, the amount of sennaol added is 0.003g, and the ratio of the two is 50:1.

[0066] Comparative Example 9

[0067] This comparative example is largely the same as Example 5, except that the amount of asiaticoside added is 0.6g, the amount of sennaol added is 0.003g, and the ratio of the two is 200:1.

[0068] Comparative Example 10

[0069] This comparative example is largely the same as Example 5, except that moist heat sterilization was not performed.

[0070] Performance Test 1

[0071] According to the rotational viscometer method of viscosity determination in 0633 of the Pharmacopoeia of the People's Republic of China (Part IV) (2020 Edition), a rotor-type viscometer was used. The rotor was immersed in the sample and rotated at a constant angular velocity (ω). The torque (M) generated by the motor rotation was measured. The viscosity of the sample was obtained using the formula η = K*M / η (K is a constant). The results are shown in Table 1. Compared with Example 5, Examples 4 and Comparative Example 1 show that the main factor affecting the sample viscosity is the content of hydroxypropyl chitosan, and the two are positively correlated. Comparative Example 2 shows that the higher the temperature of stirring and dissolving, the greater the sample viscosity. Figure 1 This more intuitively demonstrates the relationship between the viscosity change of the sample and temperature. The sample prepared in Example 5 is a solution at 8-15℃ and can flow freely when tilted; after heating to 28-37℃, the solution gels; after cooling to 8-15℃, the gel returns to a flowing liquid state, indicating that the sample is temperature sensitive and that the temperature sensitivity of the sample is not affected by moist heat sterilization.

[0072] Table 1 Viscosity tests at different temperatures

[0073]

[0074]

[0075] Performance Test 2

[0076] Sterility testing was performed according to the sterility test method 1101 of the Pharmacopoeia of the People's Republic of China (Part IV) (2020 Edition). Samples prepared in Examples 1-6 and Comparative Examples 1-9 all showed sterility, as detailed in Table 2. Compared to Examples 1-6, Comparative Example 10 did not undergo moist heat sterilization, and microorganisms began to grow on day 4, demonstrating that moist heat sterilization is necessary to ensure the shelf life of the samples.

[0077] Table 2. Sterility test results of the examples and comparative examples.

[0078]

[0079]

[0080] Performance Test 3

[0081] Following the safety principles of human trials for cosmetics, a human patch test was conducted on the mask prepared in Best Example 5 according to Chapter 7, Section 2 of the "Cosmetic Safety Technical Specifications" (2015 edition). Thirty volunteers were selected, including 10 males and 20 females, all aged 18-60 years, meeting the inclusion criteria for test volunteers. A negative control was used as a blank control. Test method: Using qualified patch testing equipment, a closed patch test method was employed. 0.02-0.025 ml of the test substance was placed in the patch device, and a hypoallergenic adhesive tape was applied to the flexor surface of the subject's forearm. After 24 hours, the test substance was removed, and skin reactions were observed at 0.5, 24, and 48 hours after removal. The results were recorded according to the skin reaction grading standards in the "Cosmetic Safety Technical Specifications" (2015 edition). The results showed no adverse skin reactions.

[0082] Table 3 shows the results of the human skin patch test in Example 5.

[0083]

[0084]

[0085] Performance Test 4

[0086] TRPV1 is widely expressed in keratinocytes, sensory neurons, and immune / inflammatory cells in the skin. It is a major cellular sensor for skin stimulation, activated and / or allosterically regulated by various thermal, mechanical, and chemical stimuli. Furthermore, it is controlled by other endogenous substances, including ATP, bradykinin, nerve growth factor (NGF), and inflammatory mediators. The TRPV1 agonist capsaicin can activate TRPV1. + Sensory nerves produce pain, burning, and itching sensations, mediating neurogenic inflammation and simultaneously causing cellular calcium deficiency. 2 + The influx of TRPV1 cells was inhibited by capsaicin, an antagonist of TRPV1. The anti-inflammatory and soothing efficacy of the samples could be evaluated by testing their effect on the relative expression level of TRPV1 mRNA in HaCaT cells.

[0087] The experiment consisted of eight groups: a negative control group, a positive control group, a model control group, and a sample group (Example 5, Comparative Example 6, Comparative Example 7, Comparative Example 8, and Comparative Example 9). Each group had four replicate wells. Cell seeding: at a cell density of 3 × 10⁻⁶ cells / well. 5Logarithmically growing HaCaT cells were seeded into 24-well plates and incubated for 24 hours in an incubator (37°C, 5% CO2). Drug administration: When the cell deposition rate in the 24-well plates reached 40%-50%, 100 μL of the test substance was added to each well. The positive control group received 1 μmol / ml capsaicin, the sample group received 0.5% (w / w), and the negative control and model control groups received no treatment. After 2 hours of incubation, 1 μmol / ml capsaicin was added to the model control, positive control, and sample groups. The negative control group received no treatment. TRPV1 detection: After 24 hours of incubation, the culture medium was removed, and the cells were washed three times with PBS. HaCaT cell mRNA was extracted and subjected to RT-qPCR, and the Ct value was measured. Using β-actin as an internal reference gene, the TRPV1 expression levels of other groups relative to the negative control group were calculated. The results are shown in Table 4. Compared to the negative control group, the TRPV1 expression level in the model control group was significantly increased; compared to the model control group, the TRPV1 expression level in the positive control group was significantly decreased, indicating that the model can evaluate the soothing efficacy of the product. The experimental results of Comparative Examples 6 and 7 with the model control group showed that Comparative Example 6 had no significant effect on TRPV1 gene expression, while Comparative Example 7 downregulated TRPV1 gene expression, indicating that sennaroside was more effective than asiaticoside in inhibiting TRPV1 gene expression. The experimental results of Example 5 with the model control group, Comparative Examples 6 and 7 showed that the samples in Example 5 all significantly downregulated TRPV1 gene expression, indicating that sennaroside and asiaticoside could synergistically inhibit TRPV1 gene expression. The experimental results of Example 5 with Comparative Examples 8 and 9 showed that the synergistic effect of sennaroside and asiaticoside was also related to the ratio of their dosage.

[0088] Table 4. Results of TRPV1 expression level detection in each group

[0089] Group Test concentration TRPV1 relative expression fold negative control group / 1.00 Model control group / 1.79 Positive control group 1μmol / ml capsicum 1.29 Sample Group - Example 5 0.5% (w / w) 0.96 Sample Group - Comparative Example 6 0.5% (w / w) 1.72 Sample Group - Comparative Example 7 0.5% (w / w) 1.49 Sample Group - Comparative Example 8 0.5% (w / w) 1.65 Sample Group - Comparative Example 9 0.5% (w / w) 1.53

[0090] Performance Test 5

[0091] Lipopolysaccharide (LPS) is a component of the cell wall of Gram-negative bacteria. In vivo, it can activate monocytes, macrophages, endothelial cells, and epithelial cells through the cell signaling system, synthesizing and releasing various cytokines and inflammatory mediators, thereby triggering a series of responses in the body. The anti-inflammatory and soothing effects of samples can be evaluated by testing the expression levels of inflammatory factors in HaCaT cells after sequential LPS stimulation and sample treatment. The experimental procedure is as follows: HaCaT cells were incubated in culture medium (37℃, 5% CO2) for 48 hours and then divided into a negative control group, an LPS model group, and a sample group (Examples 5, 6, 7, 8, and 9). The negative control group received no treatment and was cultured in medium for 48 hours. The LPS model group was treated with 1 μg / mL LPS for 24 hours, then replaced with ordinary medium for another 24 hours. The sample group was treated with 1 μg / mL LPS for 24 hours, then replaced with medium containing 1 μg / mL of the sample (Examples 5, 6, 7, 8, and 9) for another 24 hours. HaCaT cells were treated with LPS and then with samples sequentially. The cells were diluted with PBS to the detection range of the ELISA kit. The supernatant was collected according to the kit instructions. The levels of tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) in the samples were measured. After color development, the absorbance (OD value) was measured at 450 nm using a microplate reader. The concentrations of TNFα and IL-6 in the samples were calculated using a standard curve. The results are shown below. Figure 2 As shown in the figure. The experimental results show that, compared with the LPS model group, Examples 5, 6, 7, 8, and 9 can all downregulate the expression of inflammatory factors TNFα and IL-6; while Example 5 can significantly downregulate the expression of inflammatory factors TNFα and IL-6 compared with Comparative Examples 6 and 7, indicating that sennaol and asiaticoside can synergistically reduce inflammation; Example 5 can significantly downregulate the expression of inflammatory factors TNFα and IL-6 compared with Comparative Examples 8 and 9, indicating that the synergistic anti-inflammatory effect of sennaol and asiaticoside is related to the ratio of their dosage.

Claims

1. A thermosensitive recombinant collagen sterile facial mask, characterized in that, By weight percentage, it consists of the following components: Hydroxypropyl chitosan 1wt%-3.5wt%, recombinant type III humanized collagen 0.01wt%-0.5wt%, recombinant type I humanized collagen 0.01wt%-0.5wt%, glycerol 0.1wt%-10wt%, sennaol 0.001wt%-0.015wt%, asiaticoside 0.1wt%-2wt%, water balance, wherein the mass ratio of asiaticoside to sennaol is 166.7:

1. The recombinant type III humanized collagen is produced by fermentation of Pichia pastoris with accession number CGMCC No. 5021, and the recombinant type I humanized collagen is produced by fermentation of Pichia pastoris with accession number CGMCC No. 16461.

2. The thermosensitive recombinant collagen sterile facial mask according to claim 1, characterized in that, By weight percentage, it consists of the following components: Hydroxypropyl chitosan 1.5wt%, recombinant type III humanized collagen 0.1wt%, recombinant type I humanized collagen 0.1wt%, glycerol 5wt%, sennaol 0.003wt%, asiaticoside 0.5wt%, water balance.

3. The method for preparing a thermosensitive recombinant collagen sterile facial mask according to claim 1 or 2, characterized in that, The specific steps are as follows: According to the formula, under stirring conditions at 2-10℃, hydroxypropyl chitin is dissolved in water, and recombinant type III humanized collagen, recombinant type I humanized collagen, glycerin, senna phenol and asiaticoside are added in sequence. After stirring until the mixture is uniform, it is allowed to stand to obtain a semi-transparent solution. The semi-transparent solution is then packaged and sterilized by moist heat to obtain a thermosensitive recombinant collagen sterile mask.

4. The preparation method according to claim 3, characterized in that, The water is deionized water, distilled water, or water for injection.

5. The preparation method according to claim 3, characterized in that, The stirring temperature is 4-8℃.

6. The preparation method according to claim 3, characterized in that, Packaging is in retort pouches or glass bottles.

Images